Pricing Log in Create free account

Design Therapeutics, Inc. (DSGN) vs Gyre Therapeutics, Inc. (GYRE)

Design Therapeutics, Inc. and Gyre Therapeutics, Inc. are both Biotechnology companies. Design Therapeutics, Inc. and Gyre Therapeutics, Inc. are of similar size ($678.6M and $655.9M). Design Therapeutics, Inc. has the higher net margin (0.00% vs −13.7%) and the higher return on invested capital (0.00% vs −8.51%). Across the 15 metrics below, Gyre Therapeutics, Inc. leads on 8 and Design Therapeutics, Inc. on 7.

Valuation

Metric DSGN GYRE Biotechnology median
P/E n/m n/m 8.50
P/S 2,851.44 5.26 9.71
P/B 3.19 4.29 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 1,933.76 4.66 9.21
Earnings yield (11.45%) (3.29%) (33.15%)
Free cash flow yield (8.57%) (1.16%) (25.50%)

Profitability

Metric DSGN GYRE Biotechnology median
Gross margin 0.00% 94.15% 65.16%
Operating margin 0.00% (10.53%) 0.00%
Net margin 0.00% (13.73%) 0.00%
Free cash flow margin 0.00% (6.12%) 0.00%
Return on equity (34.13%) (11.75%) (56.36%)
Return on assets (32.33%) (9.08%) (48.04%)
Return on invested capital 0.00% (8.51%) 0.00%

Growth

Metric DSGN GYRE Biotechnology median
Revenue growth (TTM) — 10.72% 6.02%
EPS growth (last fiscal year) (38.64%) (60.00%) 30.26%
Revenue growth, 5-year CAGR — 40.96% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DSGN GYRE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 18.86 4.26 4.72
Net debt to EBITDA 2.68 (3.74) 0.96

Dividend

Metric DSGN GYRE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DSGN GYRE Biotechnology median
Market cap 655.86m 678.62m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack